

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.9812 • VERILY LIFE SCIENCES / SANTEN PHARMACEUTICAL / JV

SECTION 1.2

Description of the concentration

Pursuant to a Master Agreement between Verily Life Sciences LLC (a majority-owned subsidiary of Alphabet Inc., "Verily") and Santen Pharmaceutical Company, Ltd. (through its wholly-owned subsidiary, Santen Holdings U.S. Inc., "Santen"), Verily and Santen have agreed to create a jointly-controlled full-function JV. The JV will research and develop and, subject to successful development, potentially commercialise a portfolio of ophthalmology devices designed to treat or diagnose eye disorders or otherwise provide tools to assist patients, caregivers, or providers to manage overall eye health.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.